Movement Alert｜EVEREST MED Rises 5.21% in Regular Trading, Two Former Moderna mRNA Talents Join

Market Focus

Yesterday

On October 9, EVEREST MED rose 5.21% in regular trading, trading at HK$30.22/share, with Turnover of HK$8.7656 million.

The rise was driven by the appointment of Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. The appointments are intended to strengthen the company's global R&D capabilities for its mRNA technology platform and accelerate its global innovation strategy.

Chairman Wu Yifang stated that the two senior scientists will enhance the company's global mRNA R&D capabilities, supporting the clinical development of its proprietary mRNA platform and product pipeline globally, underscoring the commitment to attracting top international talent and advancing the global mRNA strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/news/1169423195"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169423195\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169423195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-09 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169423195","market":"us","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Rises 5.21% in Regular Trading, Two Former Moderna mRNA Talents Join","media":"Market Focus","content":"<p><p>On October 9, EVEREST MED rose 5.21% in regular trading, trading at HK$30.22/share, with Turnover of HK$8.7656 million.</p><p>The rise was driven by the appointment of Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. The appointments are intended to strengthen the company's global R&D capabilities for its mRNA technology platform and accelerate its global innovation strategy.</p><p>Chairman Wu Yifang stated that the two senior scientists will enhance the company's global mRNA R&D capabilities, supporting the clinical development of its proprietary mRNA platform and product pipeline globally, underscoring the commitment to attracting top international talent and advancing the global mRNA strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Rises 5.21% in Regular Trading, Two Former Moderna mRNA Talents Join</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Rises 5.21% in Regular Trading, Two Former Moderna mRNA Talents Join\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-09 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 9, EVEREST MED rose 5.21% in regular trading, trading at HK$30.22/share, with Turnover of HK$8.7656 million.</p><p>The rise was driven by the appointment of Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. The appointments are intended to strengthen the company's global R&D capabilities for its mRNA technology platform and accelerate its global innovation strategy.</p><p>Chairman Wu Yifang stated that the two senior scientists will enhance the company's global mRNA R&D capabilities, supporting the clinical development of its proprietary mRNA platform and product pipeline globally, underscoring the commitment to attracting top international talent and advancing the global mRNA strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1169423195","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169423195","pubTimestamp":1791509477,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 9, EVEREST MED rose 5.21% in regular trading, trading at HK$30.22/share, with Turnover of HK$8.7656 million.The rise was driven by the appointment of Dr. Lakshmi Srinivasan as Senior Vice...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"动向提醒|EVEREST MED常规交易涨5.21% 两名前Moderna mRNA人才加盟","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On October 9, EVEREST MED rose 5.21% in regular trading, trading at HK$30.22/share, with Turnover of HK$8.7656 million.The rise was driven by the appointment of Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. The appointments are intended to strengthen the company's global R&D capabilities for its mRNA technology platform and accelerate its global innovation strategy.Chairman Wu Yifang stated that the two senior scientists will enhance the company's global mRNA R&D capabilities, supporting the clinical development of its proprietary mRNA platform and product pipeline globally, underscoring the commitment to attracting top international talent and advancing the global mRNA strategy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}